Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Kooiman, Judith ^a   Van Rein, Nienke ^a   Spaans, Bas ^a   Van Beers, Koen A J ^a   Bank, Jonna R ^a   Van De Peppel, Wilke R ^a   Del Sol, Antonio Iglesias ^b   Cannegieter, Suzanne C ^a   Rabelink, Ton J ^a   Lip, Gregory Y H ^c   Klok, Frederikus A ^a   Huisman, Menno V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNLAND HOSPITAL   (Netherlands)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TRANSIENT ISCHEMIC ATTACK; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; FOLLOW UP; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME; VITAMIN K;

EID: 84901269541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094420     Document Type: Article

References (36)

1. Koren-Morag N, Goldbourt U, Tanne D (2006) Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 67: 224-228. 67/2/224 [pii];10.1212/01.wnl.0000229099.62706.a3 [doi].
2. Tsukamoto Y, Takahashi W, Takizawa S, Kawada S, Takagi S (2012) Chronic kidney disease in patients with ischemic stroke. J Stroke Cerebrovasc Dis 21: 547-550. S1052-3057(10)00277-6 [pii];10.1016/j.jstrokecerebrovasdis.2010.12.005 [doi].
3. Kooiman J, van de Peppel WR, van der Meer FJ, Huisman MV (2011) Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 9: 1652-1653. 10.1111/j.1538-7836.2011.04347.x [doi].
4. McManus DD, Rienstra M, Benjamin EJ (2012) An update on the prognosis of patients with atrial fibrillation. Circulation 126: e143-e146. 126/10/e143 [pii];10.1161/CIRCULATIONAHA.112.129759 [doi].
5. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, et al. (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 572-586. ki2011223 [pii];10.1038/ki.2011.223 [doi].
6. Winkelmayer WC (2013) More evidence on an abominable pairing: atrial fibrillation and kidney disease. Circulation 127: 560-562. 127/5/560 [pii];10.1161/CIRCULATIONAHA.112.000640 [doi].
7. Hart RG, Pearce LA, Asinger RW, Herzog CA (2011) Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 6: 2599-2604. CJN.02400311 [pii];10.2215/CJN.02400311 [doi].
8. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, et al. (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367: 625-635. 10.1056/NEJMoa1105594 [doi].
9. Camm AJ, Lip GY, De CR, Savelieva I, Atar D, et al. (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace 14: 1385-1413. eus305 [pii];10.1093/europace/eus305 [doi].
10. Abdelhafiz AH, Myint MP, Tayek JA, Wheeldon NM (2009) Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Ther 31: 1534-1539. S0149-2918(09)00228-8 [pii];10.1016/j.clinthera.2009.07.015 [doi].
11. Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ (2013) Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. Am J Kidney Dis. S0272-6386(13)00784-1 [pii];10.1053/j.ajkd.2013.02.381 [doi].
12. Lai HM, Aronow WS, Kalen P, Adapa S, Patel K, et al. (2009) Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis 2: 33-37.
13. Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, et al. (2013) Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 111: 1159-1164. S0002-9149(12)02648-3 [pii];10.1016/j.amjcard.2012.12.045 [doi].
14. Wieloch M, Jonsson KM, Sjalander A, Lip GY, Eriksson N, et al. (2013) Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin. Thromb Res 131: 481-486. S0049-3848(13)00008-X [pii];10.1016/j. thromres.2013.01.006 [doi].
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. .Ann Intern Med 145: 247-254. 145/4/247 [pii].
16. Pottelbergh van G, Van HL, Mathei C, Degryse J (2010) Methods to evaluate renal function in elderly patients: a systematic literature review. Age Ageing 39: 542-548. afq091 [pii];10.1093/ageing/afq091 [doi].
17. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3: 692-694. JTH1204 [pii];10.1111/j.1538-7836.2005.01204.x [doi].
18. Klok FA, Zondag W, van Kralingen KW, van Dijk AP, Tamsma JT, et al. (2010) Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med 181: 501-506. 200907-1141OC [pii];10.1164/rccm.200907-1141OC [doi].
19. Amouyel P, Mismetti P, Langkilde LK, Jasso-Mosqueda G, Nelander K, et al. (2009) INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 20: 63-69. S0953-6205(08)00136-2 [pii];10.1016/j.ejim. 2008.04.005 [doi].
20. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, et al. (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333: 11-17. 10.1056/NEJM199507063330103 [doi].
21. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, et al. (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349: 1019-1026. 10.1056/NEJMoa022913 [doi];349/11/1019 [pii].
22. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, et al. (2004) Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 126: 1938-1945. 126/6/1938 [pii];10.1378/chest.126.6.1938 [doi].
23. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69: 236-239. (Pubitemid 23069000)
24. Leeuwen van Y, Rosendaal FR, Cannegieter SC (2008) Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost 6: 451-456. JTH2874 [pii];10.1111/j.1538-7836.2007.02874.x [doi].
25. Ibrahim S, Jespersen J, Poller L (2013) The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost 11: 1540-1546. 10.1111/jth.12322 [doi].
26. Dreisbach AW, Lertora JJ (2003) The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 16: 45-50. 3011 [pii].
27. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, et al. (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332. (Pubitemid 32116374)
28. Bachmann K, Shapiro R, Mackiewicz J (1976) Influence of renal dysfunction on warfarin plasma protein binding. J Clin Pharmacol 16: 468-472.
29. Bachmann K, Shapiro R, Mackiewicz J (1977) Warfarin elimination and responsiveness in patients with renal dysfunction. J Clin Pharmacol 17: 292-299. (Pubitemid 8082193)
30. Ibrahim S, Jespersen J, Poller L (2013) The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost 11: 1540-1546. 10.1111/jth.12322 [doi].
31. Beyth RJ, Quinn L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 133: 687-695. 200011070-00010 [pii].
32. Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ (2013) Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 29: S71-S78. S0828-282X(13)00222-5 [pii];10.1016/j.cjca.2013.04.005 [doi].
33. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151. NEJMoa0905561 [pii];10.1056/NEJMoa0905561 [doi].
34. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891. 10.1056/NEJMoa1009638 [doi].
35. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992. 10.1056/NEJMoa1107039 [doi].
36. Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, et al. (2013) Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 34: 1498-1505. eht039 [pii];10.1093/eurheartj/eht039 [doi].